Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381530 | 0.88 | BRD4 (0.45) | BRD4 | |
| SCHEMBL3473525 | 0.86 | CHEK2 (0.48) | FFAR4FFAR1CYP3A4 | |
| SCHEMBL3347869 | 0.85 | FFAR1 (0.47) | BRD4FFAR4FFAR1PPARG | |
| SCHEMBL3475811 | 0.82 | GCGR (0.41) | BRD4GCGR | |
| SCHEMBL3473519 | 0.81 | FFAR1 (0.44) | BRD4FFAR4FFAR1PPARG | |
| SCHEMBL3474719 | 0.80 | MCHR1 (0.42) | BRD4SCN5A | |
| SCHEMBL3473462 | 0.80 | SMN1; SMN2 (0.47) | BRD4SCN5APPARG | |
| SCHEMBL3380300 | 0.78 | KDM4E (0.46) | KCNH2EGLN1 | |
| SCHEMBL3380246 | 0.78 | HDAC6 (0.56) | FFAR4FFAR1CYP2C9PPARGCACNA1C | |
| SCHEMBL3353025 | 0.77 | PPARG (0.45) | SCN5APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912190-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-12-16 | — | — | US | claimed |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-01 | — | — | US | claimed |
| WO-2010053757-A1 | 2 -OXOQUINOXALIN BLOCKERS OF THE LATE SODIUM CHANNEL | GILEAD PALO ALTO, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8912190-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, KCNJ2, KCNH2 | BRD4 268/4885FFAR4 363/4885FFAR1 283/4885 |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, KCNJ2, KCNH2 | BRD4 268/4885FFAR4 363/4885FFAR1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.